source
- Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancerSolstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round. The funding will support development of its lead candidate, a CTL…
- CLINUVEL to cut up to 20% of staff and move headquarters to New YorkCLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…